title: [Non-small-cell lung cancer third-line therapy with gefitinib].
abstract: The EGFR-inhibition via tyrosine-kinase-inhibitor gefitinib (Iressa) constitutes a new way to treat non-small-cell lung cancer. Recent research results enable us to better understand the basics of molecular targeted therapy (MTT). These results are helpful to re-interpret the clinical results obtained so far for gefitinib and to consider for the first time in a predictive manner factors for the selection of patients suitable for therapy. Three case reports are presented in this paper which illustrate that -- with view to the results from translational research -- the use of gefitinib offers an efficient new therapeutic modality for the treatment of chemotherapy-resistant non-small-cell lung cancer.
authors.affiliation: Klinik für Innere Medizin II Onkologie, Klinik Löwenstein, Löwenstein. jr.fischer@klinik-loewenstein.de
authors.forename: J R
authors.initials: JR
authors.lastname: Fischer
authors.forename: U
authors.initials: U
authors.lastname: Haffner
authors.forename: G M
authors.initials: GM
authors.lastname: Dietrich
authors.forename: B
authors.initials: B
authors.lastname: Spahlinger
authors.forename: D
authors.initials: D
authors.lastname: Geiger
authors.forename: H
authors.initials: H
authors.lastname: Lahm
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib